# Gland Pharma shares surge 4% on US FDA nod for Sugammadex injection 2026-08-08T09:46:24+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet Shares of Gland Pharma rose over 4% on Tuesday after the Hyderabad-based drugmaker received US FDA approval for its generic version of Sugammadex injection, used to reverse the effects of certain muscle relaxants during surgery. The approval covers 200 mg/2 mL and 500 mg/5 mL single-dose vials. The company stated its product is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme's Bridion. Gland Pharma launched the product immediately through a marketing partner. Citing IQVIA data, the firm noted that the branded product recorded US sales of approximately $1.6 billion in the 12 months ending April 2026. ## Coverage - thehindu.com Tags: generic drugs, Gland Pharma, pharma stocks, Sugammadex injection, US FDA approval Canonical: https://indianopinion.org/gland-pharma-shares-surge-4-on-us-fda-nod-for-sugammadex-injection/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/gland-pharma-shares-surge-4-on-us-fda-nod-for-sugammadex-injection/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.